uPAR-Targeted CAR Induces T-Cell Fratricide to Increase the Proportion of Desired Cells During Manufacturing
Background
A strategy has been reported for genetically editing primary human T cells to remove unwanted cells during manufacturing and increase the proportion of desired cells. Published in Molecular Therapy, the study used “directed fratricide” within the cell product as part of the manufacturing process. The approach aims to reduce reliance on extensive selection after culture.
In T-cell therapy manufacturing, cells that do not express the desired receptor or that have an exhausted or functionally impaired phenotype can remain in the final product. To reduce this heterogeneity, the researchers equipped the cells with the ability to recognize and eliminate other cells. The available abstract reports an improved cell composition but does not provide differences in cost or manufacturing time compared with existing selection methods.
Key findings
Using nonviral CRISPR genome editing, the researchers inactivated TRAC, a gene involved in the T-cell receptor (TCR) alpha chain, and introduced a chimeric antigen receptor (CAR) targeting urokinase-type plasminogen activator receptor (uPAR; CD87). The design uses uPAR expressed on some cells during manufacturing as a target for recognition by other cells.
When strong T-cell stimulation or activation was applied during manufacturing, a small fraction of cells expressed uPAR, triggering CAR-mediated killing within the product. This means that cells within the same T-cell product recognize and eliminate target-bearing cells. The abstract alone does not establish that uPAR expression is restricted to senescent or exhausted cells.
During this process, unwanted cells were eliminated while the desired cells were stimulated to proliferate. The researchers reported that these changes in cell populations could be modeled computationally and controlled using culture-medium supplements. The available abstract does not specify the supplements, their concentrations, the model equations, or the culture duration.
The maximum reported enrichment in uPAR-targeted and disialoganglioside GD2-targeted CAR-T-cell products reached a proportion of at least 99% CAR-positive, TCR-negative cells. A tendency toward a memory-like phenotype was also reported. This proportion describes the cellular composition of the product; it does not represent the yield of cells recovered from the starting population or therapeutic efficacy in patients. It should not be interpreted as a level guaranteed across all manufacturing batches.
Implications and outlook
The study presents a manufacturing strategy to expand a desired cell population by modulating cell-to-cell interactions during culture. The researchers suggest that understanding the proliferation dynamics of T-cell subsets and genetically redesigning them could accelerate cell-product manufacturing without extensive selection procedures. However, the results do not show that all existing purification steps have been eliminated or that a standard for commercial production has been established.
The available material is limited to the paper’s bibliographic information and abstract. There is insufficient evidence to interpret the reported memory-like phenotype as an increase in a specific memory T-cell subtype or as long-term persistence in the body. Efficacy in patients, in vivo safety, and performance when scaling up manufacturing are also difficult to assess from this material alone. Evaluating adoption in an actual process would require assessing recovered cell numbers, function, and batch-to-batch consistency alongside cell composition. This account of the research is based on the Molecular Therapy paper’s bibliographic record and abstract.
EMOTION_TAG: interesting
Nature Biomedical Engineering, Published June 2026.
Summary: Resolving the persistent cellular heterogeneity and product instability challenges that bottleneck primary human T cell biomanufacturing cascades, this study presents a cell-intrinsic autonomous quality control architecture. Utilizing nonviral CRISPR-Cas9 genome editing, researchers successfully engineered a targeted double-action circuit via endogenous TRAC gene disruption coupled with site-specific integration of an anti-urokinase-type plasminogen activator receptor (uPAR/CD87) Chimeric Antigen Receptor (CAR). Under manufacturing activation vectors, dysfunctional or exhausted cellular subsets selectively upregulate uPAR surface expressions, initiating a programmed directed fratricide cascade. This internal elimination vector concurrently triggers homeostatic proliferation kinetics among optimal unexhausted lines. Supplemented with predictive in silico growth models to modulate clearance velocities, this automation delivers an enriched cell product demonstrating ≥99% CAR+/TCR- therapeutic purity favoring central memory phenotypes, establishing a generalizable, non-invasive computational baseline for cell therapy scaling.
CAR-T manufacturing must secure sufficient cell numbers and function as well as the desired proportion of cells. This strategy could be evaluated as a candidate process for regulating cell elimination and proliferation during the culture of uPAR- and GD2-targeted CAR-T cells. For example, comparisons with existing selection processes could assess not only the proportion of CAR-positive, TCR-negative cells but also the final number of recovered cells, their function, and reproducibility across batches. The reported maximum composition of at least 99% alone is not enough to judge overall manufacturing efficiency. Practical adoption would require checking performance at different culture scales and confirming safety. Cost reductions and improved patient outcomes are not established findings in the available material.